ID   VKOR1_RAT               Reviewed;         161 AA.
AC   Q6TEK4;
DT   12-APR-2005, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   02-OCT-2024, entry version 133.
DE   RecName: Full=Vitamin K epoxide reductase complex subunit 1;
DE            EC=1.17.4.4 {ECO:0000269|PubMed:15640149, ECO:0000269|PubMed:23772386, ECO:0000269|PubMed:23928358};
DE   AltName: Full=Vitamin K1 2,3-epoxide reductase subunit 1;
GN   Name=Vkorc1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RX   PubMed=14765194; DOI=10.1038/nature02214;
RA   Rost S., Fregin A., Ivaskevicius V., Conzelmann E., Hoertnagel K.,
RA   Pelz H.-J., Lappegard K., Seifried E., Scharrer I., Tuddenham E.G.D.,
RA   Mueller C.R., Strom T.M., Oldenburg J.;
RT   "Mutations in VKORC1 cause warfarin resistance and multiple coagulation
RT   factor deficiency type 2.";
RL   Nature 427:537-541(2004).
RN   [2]
RP   IDENTIFICATION.
RX   PubMed=14765195; DOI=10.1038/nature02254;
RA   Li T., Chang C.-Y., Jin D.-Y., Lin P.-J., Khvorova A., Stafford D.W.;
RT   "Identification of the gene for vitamin K epoxide reductase.";
RL   Nature 427:541-544(2004).
RN   [3]
RP   MUTAGENESIS OF CYS-132 AND CYS-135, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=15640149; DOI=10.1074/jbc.m413982200;
RA   Wajih N., Sane D.C., Hutson S.M., Wallin R.;
RT   "Engineering of a recombinant vitamin K-dependent (gamma)-carboxylation
RT   system with enhanced (gamma)-carboxyglutamic acid forming capacity:
RT   evidence for a functional CxxC redox center in the system.";
RL   J. Biol. Chem. 280:10540-10547(2005).
RN   [4]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBCELLULAR LOCATION,
RP   AND CHARACTERIZATION OF VARIANTS GLN-120; GLN-128; CYS-139; PHE-139 AND
RP   SER-139.
RX   PubMed=23772386; DOI=10.1016/j.fob.2013.02.001;
RA   Matagrin B., Hodroge A., Montagut-Romans A., Andru J., Fourel I., Besse S.,
RA   Benoit E., Lattard V.;
RT   "New insights into the catalytic mechanism of vitamin K epoxide reductase
RT   (VKORC1) - The catalytic properties of the major mutations of rVKORC1
RT   explain the biological cost associated to mutations.";
RL   FEBS Open Bio 3:144-150(2013).
RN   [5]
RP   TISSUE SPECIFICITY, CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBCELLULAR
RP   LOCATION, AND FUNCTION.
RX   PubMed=23928358; DOI=10.1074/jbc.m113.457119;
RA   Hammed A., Matagrin B., Spohn G., Prouillac C., Benoit E., Lattard V.;
RT   "VKORC1L1, an enzyme rescuing the vitamin K 2,3-epoxide reductase activity
RT   in some extrahepatic tissues during anticoagulation therapy.";
RL   J. Biol. Chem. 288:28733-28742(2013).
RN   [6]
RP   VARIANTS GLN-120; GLN-128; CYS-139; PHE-139 AND SER-139, ACTIVITY
RP   REGULATION, AND FUNCTION.
RX   PubMed=15879509; DOI=10.1534/genetics.104.040360;
RA   Pelz H.J., Rost S., Hunerberg M., Fregin A., Heiberg A.C., Baert K.,
RA   MacNicoll A.D., Prescott C.V., Walker A.S., Oldenburg J., Muller C.R.;
RT   "The genetic basis of resistance to anticoagulants in rodents.";
RL   Genetics 170:1839-1847(2005).
CC   -!- FUNCTION: Involved in vitamin K metabolism. Catalytic subunit of the
CC       vitamin K epoxide reductase (VKOR) complex which reduces inactive
CC       vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for
CC       the gamma-carboxylation of various proteins, including clotting
CC       factors, and is required for normal blood coagulation, but also for
CC       normal bone development. {ECO:0000269|PubMed:15640149,
CC       ECO:0000269|PubMed:15879509, ECO:0000269|PubMed:23772386,
CC       ECO:0000269|PubMed:23928358}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[protein]-disulfide + H2O + phylloquinone = 2,3-
CC         epoxyphylloquinone + [protein]-dithiol; Xref=Rhea:RHEA:13817,
CC         Rhea:RHEA-COMP:10593, Rhea:RHEA-COMP:10594, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15759, ChEBI:CHEBI:18067, ChEBI:CHEBI:29950,
CC         ChEBI:CHEBI:50058; EC=1.17.4.4;
CC         Evidence={ECO:0000269|PubMed:15640149, ECO:0000269|PubMed:23772386,
CC         ECO:0000269|PubMed:23928358};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:13819;
CC         Evidence={ECO:0000269|PubMed:15640149, ECO:0000269|PubMed:23772386,
CC         ECO:0000269|PubMed:23928358};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[protein]-disulfide + phylloquinol = [protein]-dithiol +
CC         phylloquinone; Xref=Rhea:RHEA:57744, Rhea:RHEA-COMP:10593, Rhea:RHEA-
CC         COMP:10594, ChEBI:CHEBI:18067, ChEBI:CHEBI:28433, ChEBI:CHEBI:29950,
CC         ChEBI:CHEBI:50058; EC=1.17.4.4;
CC         Evidence={ECO:0000269|PubMed:15640149, ECO:0000269|PubMed:23772386,
CC         ECO:0000269|PubMed:23928358};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:57746;
CC         Evidence={ECO:0000269|PubMed:15640149, ECO:0000269|PubMed:23772386,
CC         ECO:0000269|PubMed:23928358};
CC   -!- ACTIVITY REGULATION: Inhibited by warfarin (coumadin) (PubMed:15879509,
CC       PubMed:23772386, PubMed:23928358). Warfarin locks VKORC1 in both redox
CC       states into the closed conformation (By similarity).
CC       {ECO:0000250|UniProtKB:Q9BQB6, ECO:0000269|PubMed:15879509,
CC       ECO:0000269|PubMed:23772386, ECO:0000269|PubMed:23928358}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:23772386, ECO:0000269|PubMed:23928358}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:23772386,
CC       ECO:0000269|PubMed:23928358}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in liver. Detected at lower levels
CC       in lung, kidney and testis. {ECO:0000269|PubMed:23928358}.
CC   -!- DOMAIN: Partially oxidized VKORC1 forms a cysteine adduct with
CC       substrates, vitamin K 2,3-epoxide, inducing a closed conformation,
CC       juxtaposing all cysteines (S-S or SH) for unimpeded electron transfer.
CC       VKOR becomes fully oxidized with an open conformation that releases
CC       reaction products, vitamin K quinone, or hydroquinone. Cys-132 and Cys-
CC       135 constitute the catalytic redox-active center. Cys-43 and Cys-51 are
CC       the cysteine pair that mediates transfer of reducing equivalents during
CC       catalysis. {ECO:0000250|UniProtKB:Q9BQB6}.
CC   -!- SIMILARITY: Belongs to the VKOR family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY423047; AAR82917.1; -; mRNA.
DR   RefSeq; NP_976080.1; NM_203335.2.
DR   AlphaFoldDB; Q6TEK4; -.
DR   SMR; Q6TEK4; -.
DR   STRING; 10116.ENSRNOP00000063977; -.
DR   BindingDB; Q6TEK4; -.
DR   ChEMBL; CHEMBL4105870; -.
DR   DrugCentral; Q6TEK4; -.
DR   GuidetoPHARMACOLOGY; 2645; -.
DR   PhosphoSitePlus; Q6TEK4; -.
DR   PaxDb; 10116-ENSRNOP00000063977; -.
DR   Ensembl; ENSRNOT00000073596.3; ENSRNOP00000063977.1; ENSRNOG00000050828.3.
DR   Ensembl; ENSRNOT00055051909; ENSRNOP00055042846; ENSRNOG00055029940.
DR   Ensembl; ENSRNOT00060042260; ENSRNOP00060035044; ENSRNOG00060024363.
DR   Ensembl; ENSRNOT00065025417; ENSRNOP00065019941; ENSRNOG00065015318.
DR   GeneID; 309004; -.
DR   KEGG; rno:309004; -.
DR   UCSC; RGD:1303107; rat.
DR   AGR; RGD:1303107; -.
DR   CTD; 79001; -.
DR   RGD; 1303107; Vkorc1.
DR   eggNOG; ENOG502S4E7; Eukaryota.
DR   GeneTree; ENSGT00940000157421; -.
DR   HOGENOM; CLU_105471_0_0_1; -.
DR   InParanoid; Q6TEK4; -.
DR   OMA; CVSTYVI; -.
DR   OrthoDB; 68850at2759; -.
DR   PhylomeDB; Q6TEK4; -.
DR   TreeFam; TF328467; -.
DR   BRENDA; 1.17.4.4; 5301.
DR   Reactome; R-RNO-6806664; Metabolism of vitamin K.
DR   PRO; PR:Q6TEK4; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000050828; Expressed in pancreas and 20 other cell types or tissues.
DR   ExpressionAtlas; Q6TEK4; baseline and differential.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; ISO:RGD.
DR   GO; GO:0048038; F:quinone binding; IEA:UniProtKB-KW.
DR   GO; GO:0047058; F:vitamin-K-epoxide reductase (warfarin-insensitive) activity; IDA:RGD.
DR   GO; GO:0047057; F:vitamin-K-epoxide reductase (warfarin-sensitive) activity; ISO:RGD.
DR   GO; GO:0007596; P:blood coagulation; ISS:UniProtKB.
DR   GO; GO:0060348; P:bone development; ISS:UniProtKB.
DR   GO; GO:0017187; P:peptidyl-glutamic acid carboxylation; ISS:UniProtKB.
DR   GO; GO:0050820; P:positive regulation of coagulation; ISO:RGD.
DR   GO; GO:0030193; P:regulation of blood coagulation; IMP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IDA:RGD.
DR   GO; GO:0042373; P:vitamin K metabolic process; ISS:UniProtKB.
DR   GO; GO:0006805; P:xenobiotic metabolic process; ISO:RGD.
DR   CDD; cd12917; VKOR_euk; 1.
DR   Gene3D; 1.20.1440.130; VKOR domain; 1.
DR   InterPro; IPR012932; VKOR.
DR   InterPro; IPR038354; VKOR_sf.
DR   InterPro; IPR042406; VKORC1/VKORC1L1.
DR   PANTHER; PTHR14519:SF0; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; 1.
DR   PANTHER; PTHR14519; VITAMIN K EPOXIDE REDUCTASE COMPLEX, SUBUNIT 1; 1.
DR   Pfam; PF07884; VKOR; 1.
DR   SMART; SM00756; VKc; 1.
PE   1: Evidence at protein level;
KW   Disulfide bond; Endoplasmic reticulum; Membrane; Oxidoreductase; Quinone;
KW   Redox-active center; Reference proteome; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..161
FT                   /note="Vitamin K epoxide reductase complex subunit 1"
FT                   /id="PRO_0000191670"
FT   TOPO_DOM        1..9
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BQB6"
FT   TRANSMEM        10..29
FT                   /note="Helical"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BQB6"
FT   TOPO_DOM        30..80
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BQB6"
FT   TRANSMEM        81..95
FT                   /note="Helical"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BQB6"
FT   TOPO_DOM        96..100
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BQB6"
FT   TRANSMEM        101..128
FT                   /note="Helical"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BQB6"
FT   TOPO_DOM        129..131
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BQB6"
FT   TRANSMEM        132..153
FT                   /note="Helical"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BQB6"
FT   TOPO_DOM        154..161
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BQB6"
FT   BINDING         80
FT                   /ligand="(S)-warfarin"
FT                   /ligand_id="ChEBI:CHEBI:87744"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BQB6"
FT   BINDING         135
FT                   /ligand="phylloquinone"
FT                   /ligand_id="ChEBI:CHEBI:18067"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BQB6"
FT   BINDING         139
FT                   /ligand="(S)-warfarin"
FT                   /ligand_id="ChEBI:CHEBI:87744"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BQB6"
FT   BINDING         139
FT                   /ligand="phylloquinone"
FT                   /ligand_id="ChEBI:CHEBI:18067"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BQB6"
FT   DISULFID        43..51
FT                   /note="Redox-active"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BQB6"
FT   DISULFID        132..135
FT                   /note="Redox-active"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BQB6"
FT   VARIANT         120
FT                   /note="L -> Q (identified in warfarin-resistant animals;
FT                   strongly reduces enzyme activity; abolishes inhibition by
FT                   warfarin)"
FT                   /evidence="ECO:0000269|PubMed:15879509,
FT                   ECO:0000269|PubMed:23772386"
FT   VARIANT         128
FT                   /note="L -> Q (identified in warfarin-resistant animals;
FT                   moderately reduces enzyme activity; decreases inhibition by
FT                   warfarin)"
FT                   /evidence="ECO:0000269|PubMed:15879509,
FT                   ECO:0000269|PubMed:23772386"
FT   VARIANT         139
FT                   /note="Y -> C (identified in warfarin-resistant animals;
FT                   strongly reduces enzyme activity; abolishes inhibition by
FT                   warfarin)"
FT                   /evidence="ECO:0000269|PubMed:15879509,
FT                   ECO:0000269|PubMed:23772386"
FT   VARIANT         139
FT                   /note="Y -> F (identified in warfarin-resistant animals;
FT                   strongly reduces enzyme activity; abolishes inhibition by
FT                   warfarin)"
FT                   /evidence="ECO:0000269|PubMed:15879509,
FT                   ECO:0000269|PubMed:23772386"
FT   VARIANT         139
FT                   /note="Y -> S (identified in warfarin-resistant animals;
FT                   strongly reduces enzyme activity; abolishes inhibition by
FT                   warfarin)"
FT                   /evidence="ECO:0000269|PubMed:15879509,
FT                   ECO:0000269|PubMed:23772386"
FT   MUTAGEN         132
FT                   /note="C->S: Loss of enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:15640149"
FT   MUTAGEN         135
FT                   /note="C->S: Loss of enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:15640149"
SQ   SEQUENCE   161 AA;  17783 MW;  BBCE9897B00807DD CRC64;
     MGTTWRSPGR LRLALCLAGL ALSLYALHVK AARARNEDYR ALCDVGTAIS CSRVFSSRWG
     RGFGLVEHVL GADSILNQSN SIFGCMFYTI QLLLGCLRGR WASILLILSS LVSVAGSLYL
     AWILFFVLYD FCIVCITTYA INAGLMLLSF QKVPEHKVKK P
//
